



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Sheena M. Loosmore
Appl'n. No. : 09/577,601
Filed : May 25, 2000
Title : CO-EXPRESSION OF RECOMBINANT PROTEINS
Grp./A.U. : 1648
Examiner : Zachariah Lucas
Docket No. : 1038-1026 MIS/jb
Date : December 2, 2002

#11
Arnold B.
w/Ext (Zman)
12/18/02

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

BY COURIER

The Commissioner of Patents
and Trademarks,
Box Amendment
Washington, D.C. 20231,
U.S.A.

12/05/2002 BABRAKA1 00000012 09577601

01 FC:1253

920.00 OP

-Ext. (3 mo.)

12/05/2002 BABRAKA1 00000012 09577601

02 FC:1806

180.00 OP

-IDS fees

AMENDMENT

Sir:

In response to the Office Action of June 4, 2002, please amend the above-identified application as follows:

In the Specification:

Please replace the paragraph beginning at page 3, line 9, with the following rewritten paragraph :

(B) cont'd.

"A second family of high molecular weight adhesion proteins has been identified in about 25% of NTHi and in encapsulated *H. influenzae* strains (refs. 11, 12, 13). The NTHi member of this second family is termed *Haemophilus influenzae* adhesin or Hia, and the homologous protein found in encapsulated strains is termed *Haemophilus influenzae* surface fibril protein or Hsf. The *hia* gene was originally cloned from an expression library using convalescent sera from an otitis media patient, which indicates that it is an important immunogen during disease. Production of the full-length recombinant Hia protein in *E. coli* appears to be toxic to the host, so a series of N-terminally truncated proteins was made as described in [copingding] United States Patent No. 6,335,182 and in PCT Patent Application No.